Skip to main content
HR 8190 116th Congress House

Biosimilar Insulin Access Act of 2020

Official title: To amend the Public Health Service Act to deem any insulin that is determined by the Secretary to be biosimilar to the reference product to be interchangeable … Show full official titleShow less

Official title: To amend the Public Health Service Act to deem any insulin that is determined by the Secretary to be biosimilar to the reference product to be interchangeable with the reference product, and for other purposes.

Introduced: September 8, 2020 Introduced by: Grothman, Glenn Republican · Wisconsin See on congress.gov
Health Blood and blood diseasesCompetition and antitrustDrug safety, medical device, and laboratory regulationDrug therapy
More subjectsShow fewer subjects
Health technology, devices, suppliesIntellectual propertyLicensing and registrationsPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 16, 2020
Sponsor introductory remarks on measure. (CR H4487)
Sep 8, 2020
Referred to the House Committee on Energy and Commerce.
Sep 8, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action September 16, 2020

Sponsor introductory remarks on measure. (CR H4487)

 Plain-English summary Congressional Research Service

Biosimilar Insulin Access Act of 2020

This bill establishes that, if the Food and Drug Administration (FDA) finds that an insulin is biosimilar to a reference product, the insulin shall be deemed interchangeable with the reference product. (A biological product is biosimilar to a reference product if the two products are highly similar and have no clinically meaningful differences; the reference product generally receives FDA approval first, but the biosimilar product is typically less expensive.)

Under current law, a biological product that is biosimilar to a reference product may be deemed interchangeable with the reference product only if it meets additional requirements. Current law provides that interchangeable products may be substituted for each other without the prescriber's involvement.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 8190: Biosimilar Insulin Access Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-HR-8190/
MLA
"H.R. 8190: Biosimilar Insulin Access Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-8190/.
Bluebook (legal)
H.R. 8190, 116th Cong. (2026), https://openamerica.io/bill/116-HR-8190/.
Markdown link
[H.R. 8190: Biosimilar Insulin Access Act of 2020](https://openamerica.io/bill/116-HR-8190/)
Report a problem